New drug picankibart aims to treat stubborn hand and foot pustules
NCT ID NCT07552454
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called picankibart in 60 adults with moderate-to-severe palmoplantar pustulosis, a painful skin condition causing pus-filled blisters on hands and feet. Participants receive injections of picankibart over nearly a year. The goal is to see if it reduces the severity of the rash and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Picankibart (a drug given as an injection under the skin)
What this could lead to
If this works, it could offer a new treatment option for people with stubborn palmoplantar pustulosis who haven't responded to standard therapies.
What could go wrong
This is a small, early-stage trial with no comparison group, so results may not be definitive. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No. 127 of West Changle Road, 710032, Xi'an, Shaanxi, China
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••